| scholarly article | Q13442814 |
| P2093 | author name string | Edgar Turner Overton | |
| Frank Tomaka | |||
| Eduardo Arathoon | |||
| Ezio Baraldi | |||
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism | Q24603957 | ||
| Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1 | Q24802369 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus | Q28582686 | ||
| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study | Q33602915 | ||
| Lipoprotein particle subclasses, cardiovascular disease and HIV infection. | Q33639078 | ||
| Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection | Q33857515 | ||
| Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy | Q33862741 | ||
| Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection | Q33907642 | ||
| Biomarkers and HIV-associated cardiovascular disease | Q34335486 | ||
| Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial | Q34647153 | ||
| Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial | Q34664004 | ||
| Dyslipidemia in the era of HIV protease inhibitors | Q35085613 | ||
| Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks | Q35127445 | ||
| Tolerability and safety of HIV protease inhibitors in adults | Q35866786 | ||
| Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia | Q35909146 | ||
| Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice | Q35913359 | ||
| Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. | Q37016796 | ||
| Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. | Q37338133 | ||
| Insulin Resistance and the cardiometabolic syndrome in HIV infection. | Q37401885 | ||
| Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials | Q37765753 | ||
| Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel | Q37773748 | ||
| Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial | Q38478387 | ||
| Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results | Q42619329 | ||
| Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis | Q42623275 | ||
| Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients | Q42976772 | ||
| Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study | Q43063917 | ||
| Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials | Q43194317 | ||
| Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. | Q43265351 | ||
| Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen | Q43585126 | ||
| Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. | Q44043469 | ||
| Impact of HIV infection and HAART on serum lipids in men. | Q44473694 | ||
| Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study | Q44486385 | ||
| Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort | Q44530878 | ||
| Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study | Q44820677 | ||
| Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial | Q44975155 | ||
| Viral load of the human immunodeficiency virus could be an independent risk factor for endothelial dysfunction | Q45486626 | ||
| Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. | Q46038574 | ||
| Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection | Q46101791 | ||
| Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. | Q46492574 | ||
| Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study | Q46505818 | ||
| Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study | Q46653141 | ||
| Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus | Q46795016 | ||
| Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. | Q54059188 | ||
| Elevated triglycerides and risk of myocardial infarction in HIV-positive persons | Q57180899 | ||
| Class of Antiretroviral Drugs and the Risk of Myocardial Infarction | Q57181081 | ||
| Protease inhibitors and cardiovascular outcomes in patients with HIV-1 | Q57955538 | ||
| Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial | Q58290838 | ||
| P433 | issue | 5 | |
| P921 | main subject | darunavir | Q3765251 |
| P304 | page(s) | 256-270 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | HIV Clinical Trials | Q15756361 |
| P1476 | title | Effect of darunavir on lipid profile in HIV-infected patients | |
| P478 | volume | 13 |
| Q64240956 | A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing? |
| Q35064091 | Cardiovascular disease risk in an aging HIV population: not just a question of biology. |
| Q38723259 | Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients |
| Q90436552 | Co-morbidities of HIV infection: role of Nef-induced impairment of cholesterol metabolism and lipid raft functionality |
| Q38577433 | Darunavir: A Review in Pediatric HIV-1 Infection |
| Q38171346 | Darunavir: a review of its use in the management of HIV-1 infection |
| Q35897840 | Dysregulation of Endoplasmic Reticulum Stress and Autophagic Responses by the Antiretroviral Drug Efavirenz |
| Q37250997 | Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial |
| Q35338096 | Epidemiology and management of antiretroviral-associated cardiovascular disease |
| Q54219922 | HIV and cardiovascular disease: defining the unmeasured risk. |
| Q30239101 | HIV and its relationship to insulin resistance and lipid abnormalities. |
| Q47602387 | Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study |
| Q37195784 | Infectious and Non-infectious Etiologies of Cardiovascular Disease in Human Immunodeficiency Virus Infection |
| Q38108736 | Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS. |
| Q41934612 | Metabolic health across the body mass index spectrum in HIV-Infected and HIV-Uninfected Men. |
| Q40145206 | Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). |
Search more.